Our R&D mission

Initially, we started off as a pioneer in DNA methylation, exploiting this natural phenomenon with our proprietary technologies as a rich source of biomarkers.

Today, we are developing and commercializing blood-based tests for the detection of cancer, using our proprietary DNA methylation biomarkers. Our high-performing, minimally-invasive tests are addressing high medical needs. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as liver, lung and colorectal cancer.

While we are dedicated to developing molecular diagnostic tests for cancer, we continuously improve our proprietary technology to maintain leadership in DNA methylation-based diagnostics.